公开(公告)号：US10045978B2

公开(公告)日：2018-08-14

申请号：US14957201

申请日：2015-12-02

申请人： AB SCIENCE

发明人： Alain Moussy ,  Jean-Pierre Kinet

IPC分类号： A61K31/496 ,  A61K9/00 ,  A61K31/095

摘要： The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.

公开(公告)号：US10028918B2

公开(公告)日：2018-07-24

申请号：US14399335

申请日：2013-05-01

申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.

发明人： Parimala Nacharaju ,  Adam J. Friedman ,  Joel M. Friedman

IPC分类号： A61K9/00 ,  A61K31/00 ,  A61K9/51 ,  A61K31/198 ,  A61K31/401 ,  A61K9/14 ,  A61K9/19 ,  A61K31/095

摘要： Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.

公开(公告)号：US20180133211A1

公开(公告)日：2018-05-17

申请号：US15574677

申请日：2016-05-19

申请人： Mayo Foundation for Medical Education and Research

发明人： Andre J. van Wijnen ,  Scott M. Riester ,  Emily T. Camilleri ,  Amel Dudakovic ,  Roman Thaler ,  John W. Sperling

IPC分类号： A61K31/496 ,  A61P19/10 ,  A61P19/08 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/26 ,  A61K31/385 ,  A61K31/095

CPC分类号： A61K31/496 ,  A61K31/095 ,  A61K31/26 ,  A61K31/385 ,  A61K31/4439 ,  A61K31/5355 ,  A61K31/5377 ,  A61P19/08 ,  A61P19/10 ,  A61K2300/00

摘要： This document provides methods and materials involved in promoting new bone formation for the treatment of medical conditions such as osteoporosis, bone defects, bone injury (e.g., fractures) implant ingrowth, and joint/spine fusions. For example, methods and materials for using sulforaphane and/or EZH2 polypeptide inhibitors (e.g., GSK126 or UNC1999) to treat osteoporosis, bone fractures and defects, implant ingrowth, and joint fusions are provided.

公开(公告)号：US20180117074A1

公开(公告)日：2018-05-03

申请号：US15801990

申请日：2017-11-02

申请人： N.V. Nutricia

发明人： Nick VAN WIJK

IPC分类号： A61K31/714 ,  A61K45/06 ,  A61K31/14 ,  A61K31/095 ,  A61K31/7072 ,  A61K31/519 ,  A61K31/202 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4415

CPC分类号： A61K31/714 ,  A61K31/095 ,  A61K31/14 ,  A61K31/202 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7072 ,  A61K45/06 ,  A61K2300/00

摘要： The invention pertains to the use of a preparation for the manufacture of a composition for preventing or treating impaired plasma levels of one or more polar lipids such as phosphatidylcholines [PC] selected from the group consisting of phosphatidylcholine diacyl C36:6 [PC aa C36:6], phosphatidylcholine diacyl C38:0 [PC aa C38:0], phosphatidylcholine diacyl C38:6 [PC aa C38:6], phosphatidylcholine diacyl C40:6 [PC aa C40:6] and phosphatidylcholine acyl-alkyl C40:6 [PC ae C40:6] in a preclinical AD or MCI subject or a subject with a high likelihood of developing AD or MCI, and wherein said subject is administered with a composition comprising at least one, preferably at least two, most preferably all B vitamins selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9.

公开(公告)号：US09937176B2

公开(公告)日：2018-04-10

申请号：US15505767

申请日：2015-09-02

申请人： NIPPON SHINYAKU CO., LTD.

发明人： Yoshinobu Shiba ,  Satoshi Akiyama

IPC分类号： A61K31/506 ,  C07D513/04 ,  A61K31/25 ,  A61K31/135 ,  A61K31/095 ,  A61K31/381

CPC分类号： A61K31/506 ,  A61K31/095 ,  A61K31/135 ,  A61K31/25 ,  A61K31/381 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/14 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D513/04

摘要： The invention provides a pyrazolothiazole compound of the formula [I], or a pharmaceutically acceptable salt thereof: The compound of the invention has JAK1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.

公开(公告)号：US09937167B2

公开(公告)日：2018-04-10

申请号：US15370973

申请日：2016-12-06

申请人： AQUINOX PHARMACEUTICALS (CANADA) INC.

发明人： Lloyd F. Mackenzie ,  Thomas B. Macrury ,  Curtis Harwig ,  David Bogucki ,  Jeffery R. Raymond ,  Jeremy D. Pettigrew ,  Vladimir Khlebnikov ,  Rudong Shan

IPC分类号： C07D213/82 ,  C07C49/83 ,  A61K31/4965 ,  A61K31/44 ,  A61K31/05 ,  A61K31/12 ,  A61K31/122 ,  A61K31/135 ,  A61K31/085 ,  A61K31/192 ,  A61K31/09 ,  A61K31/167 ,  A61K31/165 ,  A61K31/277 ,  A61K31/095 ,  A61K31/166 ,  A61K31/4402 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/495 ,  A61K31/155 ,  A61K31/4406 ,  A61K31/4465 ,  A61K31/10 ,  A61K31/443 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/496

CPC分类号： A61K31/4965 ,  A61K31/05 ,  A61K31/085 ,  A61K31/09 ,  A61K31/095 ,  A61K31/10 ,  A61K31/12 ,  A61K31/122 ,  A61K31/135 ,  A61K31/155 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/192 ,  A61K31/277 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/496 ,  C07B2200/07 ,  C07C39/17 ,  C07C43/21 ,  C07C43/215 ,  C07C43/23 ,  C07C49/83 ,  C07C49/835 ,  C07C49/84 ,  C07C62/32 ,  C07C62/34 ,  C07C217/84 ,  C07C225/20 ,  C07C233/26 ,  C07C233/28 ,  C07C233/31 ,  C07C233/32 ,  C07C233/60 ,  C07C233/76 ,  C07C235/82 ,  C07C237/08 ,  C07C255/47 ,  C07C275/26 ,  C07C275/64 ,  C07C279/16 ,  C07C311/07 ,  C07C311/17 ,  C07C311/18 ,  C07C317/22 ,  C07C323/20 ,  C07C2602/28 ,  C07D211/66 ,  C07D213/38 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D213/89 ,  C07D233/64 ,  C07D241/24 ,  C07D249/08 ,  C07D295/112 ,  C07D295/215 ,  C07D401/12 ,  C07D405/12

摘要： Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

公开(公告)号：US09913820B2

公开(公告)日：2018-03-13

申请号：US15260238

申请日：2016-09-08

申请人： Board of Regents, The University of Texas System

发明人： Issam Raad ,  Joel Rosenblatt

IPC分类号： A61K31/21 ,  A61K33/40 ,  A61K31/194 ,  A61K31/19 ,  A61K9/00 ,  A61K31/095 ,  A61K31/10 ,  A61K9/08 ,  A61L29/16 ,  A61K31/045 ,  A61K31/16 ,  A61K31/145 ,  A61K31/185 ,  A61K31/191 ,  A61K31/198 ,  A61K31/20 ,  A61K31/327 ,  A61K31/7004 ,  A61K33/42 ,  A61L31/16 ,  A61L15/46 ,  A61L17/00 ,  A61K45/06 ,  A01N31/02 ,  A01N33/20 ,  A01N37/16 ,  A01N37/36 ,  A01N37/44 ,  A01N59/00 ,  C11D3/20 ,  C11D3/39 ,  C11D7/26 ,  C11D11/00 ,  A01N25/02 ,  A01N33/16 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/24

CPC分类号： A61K31/21 ,  A01N25/02 ,  A01N31/02 ,  A01N33/16 ,  A01N33/20 ,  A01N37/16 ,  A01N37/36 ,  A01N37/44 ,  A01N59/00 ,  A61K9/0014 ,  A61K9/08 ,  A61K31/045 ,  A61K31/095 ,  A61K31/10 ,  A61K31/145 ,  A61K31/16 ,  A61K31/185 ,  A61K31/19 ,  A61K31/191 ,  A61K31/194 ,  A61K31/198 ,  A61K31/20 ,  A61K31/327 ,  A61K31/7004 ,  A61K33/40 ,  A61K33/42 ,  A61K45/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A61K47/24 ,  A61L15/46 ,  A61L17/005 ,  A61L29/16 ,  A61L31/16 ,  A61L2202/21 ,  A61L2300/216 ,  A61L2300/404 ,  C11D3/2003 ,  C11D3/2065 ,  C11D3/2075 ,  C11D3/3947 ,  C11D7/261 ,  C11D7/265 ,  C11D11/0041 ,  A61K2300/00 ,  A01N37/02 ,  A01N43/16

摘要： Provided are antimicrobial solutions comprising a glyceryl nitrate (e.g., glyeryl trinitrate) in combination with a chelator (e.g., citrate), a peroxide, a fatty acid, and/or an alcohol (e.g., ethanol). In various aspects these components may synergistically act to kill or reduce the growth of microbes, such as bacteria or fungi, present in a biofilm.

公开(公告)号：US09889103B2

公开(公告)日：2018-02-13

申请号：US15696912

申请日：2017-09-06

申请人： NaCuity Pharmaceuticals, Inc.

发明人： John C. Warner ,  Srinavasa Cheruku ,  Sambaiah Thota ,  John W. Lee

IPC分类号： C07C311/29 ,  C07C321/00 ,  A61K31/195 ,  A61K38/04 ,  A61K31/095 ,  A61K31/16 ,  A61K31/198

CPC分类号： A61K31/195 ,  A61K31/095 ,  A61K31/16 ,  A61K31/198 ,  A61K38/04 ,  C07C311/29 ,  C07C319/12 ,  C07C321/00 ,  C07C323/59 ,  C07C323/60

摘要： The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.

公开(公告)号：US09763902B2

公开(公告)日：2017-09-19

申请号：US15300092

申请日：2015-03-27

申请人： NaCuity Pharmaceuticals, Inc.

发明人： John C. Warner ,  Srinavasa Cheruku ,  Sambaiah Thota ,  John W. Lee

IPC分类号： C07C311/29 ,  C07C321/00 ,  A61K31/195 ,  A61K38/04 ,  A61K31/095 ,  A61K31/16 ,  A61K31/198

CPC分类号： A61K31/195 ,  A61K31/095 ,  A61K31/16 ,  A61K31/198 ,  A61K38/04 ,  C07C311/29 ,  C07C319/12 ,  C07C321/00 ,  C07C323/59 ,  C07C323/60

摘要： The present application discloses an efficient process for the preparation of N-acetyl-L-cysteine amide (NACA) starting with N-acetyl-L-cysteine.

公开(公告)号：US09750755B2

公开(公告)日：2017-09-05

申请号：US14741701

申请日：2015-06-17

申请人： DeLaval Holding AB

发明人： Fahim U. Ahmed ,  Alex Skender ,  Chris Foret ,  Thomas C. Hemling ,  N. Camelia Traistaru

IPC分类号： A61K31/60 ,  A61K31/192 ,  A61K31/375 ,  A01N37/02 ,  A61K9/00 ,  A61K9/12 ,  A61K31/095 ,  A61K31/19 ,  A61K31/191 ,  A61K31/194 ,  A61K31/20 ,  A61K31/201 ,  A61K47/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20

CPC分类号： A61K31/60 ,  A01N37/02 ,  A61K9/0017 ,  A61K9/12 ,  A61K31/095 ,  A61K31/19 ,  A61K31/191 ,  A61K31/192 ,  A61K31/194 ,  A61K31/20 ,  A61K31/201 ,  A61K31/375 ,  A61K47/08 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20 ,  A01N25/30 ,  A01N2300/00

摘要： A liquid antimicrobial composition comprising an organic acid and one or more anionic surfactants is disclosed. In one embodiment, the organic acid is lactic acid and the anionic surfactant is sodium octane sulfonate. In a preferred embodiment, the antimicrobial solution is formulated as a teat dip for lactating animals, particularly cows. In other embodiments, the antimicrobial compositions may be used in personal care, hard surface care including hard surface disinfection in households, food processing, hospitals, restaurants, hotels, showers, or topically as hand soaps, surgical scrubs, and hoof disease mitigators.